1. The Center of Gravity of Zhejiang Pharma Lies in the Unseen Raw-Material End

When people think of a province's pharmaceutical industry, they tend to picture innovative drugs, star products and capital-market stories first. But the real weight of Zhejiang's pharmaceutical manufacturing rests precisely where outsiders rarely look: on two layers of base supply, chemical active pharmaceutical ingredients (APIs) and nutritional raw materials.

APIs are the upstream of formulations, the active substances that exist before a pill or injection takes shape; nutritional raw materials such as vitamins and methionine are bulk fine chemicals that connect to feed at one end and to food and health products at the other. Neither faces patients directly, and their value added is often judged lower than that of end formulations, yet they form the least replaceable link in the global pharmaceutical and nutrition chain: whoever can make these raw materials stably, compliantly and cheaply holds the lifeline of everything downstream. The story of Zhejiang's pharmaceutical manufacturing begins from this raw-material end.

The Institute treats Zhejiang pharmaceutical manufacturing as a regional sample not for how many innovative drugs it has launched, but because it clearly shows how a major industrial province secures a global position by "making raw materials": Taizhou turned chemical APIs into a national-level export base, Xinchang and Shaoxing took vitamins to global dominance, and Hangzhou branched off into formulations, aesthetic medicine and industrial microbiology. This article endorses no investment judgment. It only sets out the real landscape of each of these three lines and honestly points to the hidden risks of each.

2. Taizhou: China's Only National-Level Chemical API Export Base

To understand Zhejiang pharma, one cannot get past Taizhou.

Taizhou holds China's only national-level chemical API export base and is a genuine "API capital." Its weight rests not on concepts but on hard export share: Taizhou's chemical API exports account for roughly one-third of the province and one-tenth of the country. Locally, a complete chain has been built from chemical feedstock to intermediates to APIs to formulations, and this tightly meshed upstream-downstream system is hard to replicate elsewhere in the short term. In the national rankings of top pharmaceutical counties and cities, Taizhou alone takes a substantial share, a regional density rare across the country.

What sustains this base is a group of API firms rooted in Taizhou for decades. Hisun Pharmaceutical, Huahai Pharmaceutical, Xianju Pharmaceutical and Jiuzhou Pharmaceutical each hold a place in niche fields such as antibiotics, anti-tumor agents, cardiovascular drugs and hormone APIs, and together they built up Taizhou's reputation as a "world pharmacy." Among them, Hisun Pharmaceutical posted operating revenue of about 9.787 billion yuan in 2024, returning to profit after several rocky years; Jiuzhou Pharmaceutical moved from traditional APIs into contract research and manufacturing services, one of the few Taizhou firms to rank near the front nationally in its category, marking the direction of API firms climbing toward higher-value links.

The foundation of the Taizhou line is process and compliance. Chemical APIs look like bulk goods, yet the threshold to enter regulated markets in Europe and the United States and pass on-site inspections by international drug regulators is not low: it tests the hard skills of fermentation, synthesis and quality systems. Taizhou holds its ground precisely through this manufacturing and compliance capability accumulated over decades, not through being cheap.

3. Huahai Pharmaceutical: A Sample of Climbing from APIs to Formulation Exports

Among Taizhou's many drugmakers, Huahai Pharmaceutical deserves a separate look, because it walked the path every API firm most wants but finds hardest to complete: from selling raw materials, to selling formulations, to selling formulations into the mainstream markets of Europe and the United States.

Huahai Pharmaceutical, headquartered in Linhai, Taizhou, is the textbook case of the "API plus formulation" vertically integrated model. It posted operating revenue of about 9.547 billion yuan in 2024, up nearly 15 percent year on year; more importantly, by its own disclosure, the company's overseas revenue share has exceeded 47 percent, a considerable portion from selling generic formulations directly into regulated markets such as the United States. The difficulty of this goes far beyond making the drug: it means obtaining formulation approvals for the U.S. market, withstanding repeated inspections by the other side's regulators, and standing firm in the fierce price competition after patent cliffs. Huahai is among the earliest domestic firms to complete this path.

Its significance lies in answering a question that troubles every API firm: can selling raw materials carry a company upstream, can it stop earning only the thinnest layer of processing fee? Huahai's answer is to build the active ingredients it knows best into downstream formulations, then use compliance capability to sell those formulations into higher-value overseas markets. Whether it can keep going depends on whether it can continually add new high-barrier products amid centralized-procurement price cuts and the red sea of overseas generics, rather than living off the stock of old products.

4. Xinchang and Shaoxing: Global Suppliers of Vitamins

Moving the gaze from coastal Taizhou to the mountains of central Zhejiang, another face of Zhejiang's pharmaceutical manufacturing appears: nutritional raw materials, and vitamins above all.

Xinhecheng, in Xinchang, Shaoxing, is the most striking firm on this line. Grounded in fine chemicals and led by nutritional products and flavors and fragrances, it is one of the world's major vitamin producers, with vitamin E and vitamin A output and sales ranking among the global leaders. In 2024, Xinhecheng posted operating revenue of about 21.6 billion yuan and net profit attributable to shareholders of about 5.869 billion yuan, both record highs, with the nutritional-products segment contributing close to 70 percent of revenue. It has also turned methionine into a new growth pole, with related project capacity reaching 300,000 tonnes per year. That a fine-chemical firm in a mountain county can hold pricing power over a global bulk fine chemical like vitamins is in itself the weightiest entry in Zhejiang pharma.

Xinhecheng is not alone. The global markets for vitamin E and vitamin A have long been dominated by four firms, two of which are in Zhejiang: Xinhecheng and Zhejiang Medicine. In other words, a substantial share of the world's supply of vitamin E and vitamin A stands on two Zhejiang firms. This is a peculiar industrial position: out of the spotlight, yet genuinely embedded in the raw-material chains of global feed, food and health products.

But the hidden risk of this line lies precisely in its "bulk" nature. Vitamins are a typical cyclical commodity, with prices swinging widely on supply and demand; the surge in 2024 results owed much to a market recovery, and once the market turns down, profit elasticity is equally large. Add tariffs and trade friction in overseas markets, which may cut off part of export demand. For a firm that has taken its product to global dominance, the hardest test is not technology but how to smooth the violent swings in results amid the twin volatility of cycles and trade barriers.

5. Hangzhou: A Separate Path in Formulations, Aesthetic Medicine and Industrial Microbiology

Taizhou's APIs and Xinchang's vitamins both lean toward the upstream and raw-material end of the chain. For Zhejiang pharma to fill in the link close to the end market, it relies on Hangzhou.

Hangzhou's Huadong Medicine is the representative. Founded in 1993 and headquartered in Hangzhou, this listed firm covers four segments: pharmaceutical industry, pharmaceutical commerce, aesthetic medicine and industrial microbiology, one of the few comprehensive enterprises in Zhejiang pharma spanning raw materials, formulations and consumer healthcare. In 2024, Huadong Medicine posted combined operating revenue of about 41.9 billion yuan, among the larger figures by revenue among Zhejiang's pharmaceutical manufacturers; its pharmaceutical-industry segment alone brought in about 13.8 billion yuan, supported by core generics such as acarbose and a stream of newly launched innovative products, with R&D investment also rising steadily.

Even more notable is its "separate venture." Facing pressure from centralized procurement cutting prices on core generics, Huadong Medicine put considerable effort into aesthetic medicine and industrial microbiology; its aesthetic-medicine business held steady growth in 2024, and its subsidiary's aesthetic products have reached meaningful scale. This is a textbook approach of using consumer healthcare to hedge the price risk of traditional pharma: when drug-side profits are squeezed by procurement, it leans on self-pay, brand-driven aesthetic medicine to make up the difference.

The value of this link lies in its character being completely different from the first two lines: Taizhou competes on the process and compliance of APIs, Xinchang on the global scale of vitamins, while the Hangzhou line competes on the end market, getting drugs into patients' hands and building aesthetic medicine into a consumer brand. Its scale on the formulation side is already not small, yet it also most directly bears the twin pressures of procurement price cuts and competition in consumer healthcare.

6. Hidden Risks and the Institute's Judgment

Pulling the three lines together, Zhejiang's pharmaceutical manufacturing takes a shape of "very strong upstream, filling in downstream": Taizhou holds China's only national-level chemical API export base, with chemical API exports at one-tenth of the country and one-third of the province, and Hisun, Huahai, Xianju and Jiuzhou anchor the API capital, a sample of global supply driven by process and compliance; Xinhecheng in Xinchang and Zhejiang Medicine in Shaoxing took vitamin E and vitamin A to global dominance, with Xinhecheng's 2024 revenue at about 21.6 billion yuan, a sample of global supply of raw-material-grade nutrition; Hangzhou's Huadong Medicine, with revenue of 41.9 billion yuan, fills in the link close to the end market through formulations, aesthetic medicine and industrial microbiology. The three lines connect to global raw-material chains at one end and to domestic patients and consumers at the other, differing greatly in structure.

Their hidden risks divide clearly too. The API-and-formulation export line of Taizhou and Huahai depends heavily on access to and prices in regulated overseas markets; if overseas generic competition intensifies and trade barriers rise, the export dividend narrows. The vitamin line of Xinchang and Shaoxing is tied to bulk-commodity cycles, with results surging in good times and profits plunging in bad ones, made naturally volatile when tariff disturbances are layered on. The formulation line in Hangzhou faces the continuing price cuts of domestic procurement; hedging with aesthetic medicine works, but competition in consumer healthcare is itself intensifying. Each line has its own weakness, and it is hard to capture them in a single judgment.

For upstream suppliers serving pharmaceutical manufacturing, whether sales teams in fermentation raw materials, chemical intermediates, pharmaceutical equipment, or testing and packaging materials, reaching Zhejiang's API, nutritional-product and formulation factory customers in volume is possible through Tianxia Gongchang, which lets you filter the factory directory and decision-maker contacts of Zhejiang's pharmaceutical manufacturing along the two dimensions of region and industry, turning upstream sales prospecting from door-to-door inquiry into reading off a map.

The Institute's view is this: the real confidence of Zhejiang's pharmaceutical manufacturing lies not in how many innovative drugs any one firm can list, but in how it turned "making raw materials," the hard, unglamorous work others look down on, into a hard currency the world cannot do without. Taizhou's APIs and Xinchang's vitamins both occupy a position that is "not on the stage, yet lodged in the throat." What to watch next is whether this raw-material-end global advantage can extend upstream: whether Taizhou and Huahai can continually turn the compliance capability of raw materials into exports of high-barrier formulations, whether Xinchang and Shaoxing can hold pricing power through the vitamin cycle, and whether Hangzhou can let aesthetic medicine and innovative drugs truly take over the space ceded by generic price cuts. These three questions share no common solution, yet together they decide whether Zhejiang pharma can move from "the world's raw-material workshop" toward a pharmaceutical powerhouse that stands firm on both raw materials and end products. An industry long overshadowed by the innovative-drug narrative often carries its true weight in the raw-material drums and fermentation tanks that never appear in headlines.

Data Sources

  • Tianxia Gongchang (Zhejiang pharmaceutical manufacturing factory directory and industry data)
  • Zhejiang Online Taizhou Channel and the Taizhou Municipal Government: Taizhou's share among top national pharmaceutical counties and cities, the national-level chemical API export base, the share of chemical API exports in the province and the country, and the positioning as API capital and world pharmacy
  • Zhejiang Huahai Pharmaceutical 2024 Annual Report: Huahai's operating revenue, growth rate, API-plus-formulation integrated model and overseas revenue share
  • Zhejiang Hisun Pharmaceutical 2024 Annual Report summary: Hisun's operating revenue and return to profit
  • Xinhecheng 2024 results reporting and financial statements: Xinhecheng's operating revenue, net profit attributable to shareholders, global position in vitamin E and vitamin A, nutritional-products share and methionine capacity
  • Global vitamin industry research material: vitamin E and vitamin A markets dominated by four firms, among them Xinhecheng and Zhejiang Medicine
  • Huadong Medicine 2024 Annual Report and related reporting: Huadong Medicine's operating revenue, four business segments, pharmaceutical-industry sales revenue, scale of aesthetic-medicine business and R&D investment
  • Public annual results and industry research on Apeloa Pharmaceutical, Jiuzhou Pharmaceutical and Guobang Pharmaceutical: Zhejiang as the province with the most listed API enterprises, Apeloa's API and intermediate business in Hengdian, and Jiuzhou's contract research and manufacturing services